ArticleCurrent oncology (Toronto, Ont.)2024

Durable Objective Response to Lurbinectedin in Small Cell Bladder Cancer with TP53 Mutation: A Molecular-Directed Strategy.

Mohammad Jad Moussa et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.